SIGA Technologies Q1 2026: Strengthening Biodefense

SIGA Technologies, focused on smallpox biodefense, reported a Q1 2026 loss but maintained a robust cash position, enabling a special dividend. They expect significant TPOXX deliveries this quarter and have secured U.S. government funding for pediatric work. Despite Europes CHMP withdrawing mpox support, SIGAs smallpox approvals remain intact. Their pipeline is active, with pediatric Phase I study results due by year-end and post-exposure prophylaxis data headed to the FDA. An exclusive deal with Hikma expands TPOXXs global reach. SIGAs disciplined approach positions them well in the growing bio-threat preparation market. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/1f59eddcd9d4d40b